Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 Abril 2024 - 8:00AM
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics to
treat rare fibro-inflammatory diseases with high unmet need, today
announced it will host a live key opinion leader (KOL) virtual
event on primary sclerosing cholangitis (PSC) on Wednesday, April
10, 2024 at 10:00 AM ET. To register, click here.
The event, “Breaking New Ground: Expert Perspectives on Primary
Sclerosing Cholangitis,” will feature Christopher Bowlus, MD (UC
Davis Health), Ricky Safer (PSC Partners Seeking a Cure), and
Massimo Pinzani, MD, PhD, (UCL Institute for Liver and Digestive
Health, UPMC ISMETT), who will provide clinical and patient
perspectives on PSC, a devastating rare liver disease with no
FDA-approved therapies. They will discuss the urgent need for new
PSC treatments and emerging developments that could facilitate new
drug approvals.
Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt
Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC
clinical trial that will report topline results midyear 2024.
CM-101 is a dual mechanism first-in-class monoclonal antibody that
neutralizes CCL24, a soluble protein that is a key driver of
inflammatory and fibrotic pathways central to PSC and other
fibro-inflammatory diseases.
A Q&A session will follow the presentations.
About Christopher Bowlus, MDChris Bowlus, MD is
the Lena Valente Professor and Chief of the Division of
Gastroenterology and Hepatology at the University of California
Davis School of Medicine. Dr. Bowlus has an active research program
bridging the basic and clinical aspects of PSC and primary biliary
cholangitis (PBC), with the goal of bringing more effective
treatments to patients. He is a founding member of the
International PSC Study Group and leads the U.S,-based Consortium
for Autoimmune Liver Disease. Dr. Bowlus is also active in
supporting patient advocacy, serving as Co-Chair of the Scientific
and Medical Advisory Committee of PSC Partners Seeking a Cure. He
received his BA degree from the University of California San Diego
and his MD degree from the St. Louis University School of Medicine.
Dr. Bowlus completed a Fellowship in Gastroenterology at the Yale
University School of Medicine.
About Ricky SaferRicky Safer is a patient
living with PSC and Founder and CEO of PSC Partners Seeking a Cure,
a non-profit organization whose mission is to drive PSC research to
identify treatments and a cure and provide education and support
for those impacted by PSC. PSC Partners collaborates with
researchers, clinicians, industry and regulators to accelerate PSC
research and drug development. Its many initiatives include
creation of a PSC Patient Registry, an international database to
create a synthetic arm for later stage clinical trials, and
regulatory-grade, validated Patient-Reported Outcome Measures for
major PSC symptoms. Safer serves on a number of healthcare-related
boards and steering committees. She is a frequent presenter at
medical conferences and has co-authored numerous posters and
peer-reviewed scientific studies. Safer received a BA with honors
from the University of Michigan and an MA degree from Johns Hopkins
University.
About Massimo Pinzani, MD, PhD, FRCP,
FAASLDProfessor Massimo Pinzani is a clinical and
translational hepatologist and Emeritus Professor of Medicine at
University College London (UCL). Until 2023 he was Sheila Sherlock
Chair of Hepatology and Director of the UCL Institute for Liver and
Digestive Health. Prof. Pinzani is a pioneer in researching
cellular and molecular mechanisms of liver fibrosis and diagnostic
and therapeutic approaches to managing liver fibrotic diseases. He
has authored more than 300 peer-reviewed publications and has
served as a board member of major hepatology and gastroenterology
organizations, including the European Association for the Study of
the Liver (EASL), and as an associate editor of major journals in
the field. Prof. Pinzani was recently appointed Scientific Director
of UPMC-ISMETT, a renowned center for transplantation and advanced
specialized therapies in Palermo, Italy.
About CM-101Chemomab is assessing CM-101 as a
potential treatment for PSC in the Phase 2 SPRING trial. CM-101 is
a first-in-class monoclonal antibody that neutralizes CCL24, a
soluble protein that helps drive the inflammatory and fibrotic
pathways central to PSC and other fibro-inflammatory diseases. In
clinical and preclinical studies, CM-101 appears safe, with the
potential to treat multiple fibro-inflammatory disorders. Data from
a Phase 2a liver fibrosis trial in nonalcoholic steatohepatitis
(NASH) patients showed consistent, positive improvements in key
inflammatory and fibrogenesis-related biomarkers, including several
that may serve as a potential bridge to activity in PSC. Patient
enrollment in the Phase 2 SPRING trial has been completed and a
readout of topline data is expected midyear 2024. CM-101 has Orphan
Drug status in the U.S. and E.U. and was awarded FDA Fast Track
designation.
A recording of the PSC KOL webinar will be available following
the live session on Chemomab’s website at Chemomab Investor
Relations - Presentations.
About Chemomab Therapeutics Ltd.Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab’s CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready. For more information about
Chemomab, visit chemomab.com.
Contact:
Media and Investors:Barbara LindheimConsulting
Vice President, Investor & Public Relations, Strategic
CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024